Oct. 4 at 5:07 AM
$RGBP Share Structure Update Common Shares 10/3/2025...
There were 40,000,000 shares added to the Outstanding Shares which were issued in advance to David Koos and Harry Lander for their upcoming work on the Phase I clinical trial for HemaXellerate, as noted in today's 8-K filing.
And as anticipated, those shares were also added to the "Restricted Shares" because they will not become fully vested unrestricted shares until the company successfully completes the Phase I trial for HemaXellerate.
So not only will the company management be the holders of those shares, but they will also be locked up as restricted shares for at least a year or longer and will not be a factor of added dilution to the publicly traded float.
Also of note, along with the 10M shares that were issued to David Koos a couple months ago, the company's management will now be holding 62.5% of the current outstanding shares. And I am totally fine with that!
Best wishes everyone for 2025! 😊🤙🍀